FDA
-
-
-
-
-
-
-
Bayer to present cancer trial data at ASCO 2026 meeting
-
-
-
-
-
-
-
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
-
-
-
-
-
-
-
Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA
-
-
-
-
-
-
-
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
-
-
-
-
-
-
-
Bayer receives FDA approval for Lynkuet menopause hot flash treatment
-
-
-
-
-
-
-
Bayer AG (BAYGN) announces FDA approval for Jivi
-
-
-
-
-
-
-
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the Second Quarter 2022
-
326,216 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

